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A B S T R A C T   
Ingested inorganic nitrate (NO3⁻) has multiple effects in the human body including vasodilation, inhibition of 
platelet aggregation, and improved skeletal muscle function. The functional effects of oral NO3⁻ involve the in 
vivo reduction of NO3⁻ to nitrite (NO2⁻) and thence to nitric oxide (NO). However, the potential involvement of S- 
nitrosothiol (RSNO) formation is unclear. We hypothesised that the RSNO concentration ([RSNO]) in red blood 
cells (RBCs) and plasma is increased by NO3⁻-rich beetroot juice ingestion. In healthy human volunteers, we 
tested the effect of dietary supplementation with NO3⁻-rich beetroot juice (BR) or NO3⁻-depleted beetroot juice 
(placebo; PL) on [RSNO], [NO3⁻] and [NO2⁻] in RBCs, whole blood and plasma, as measured by ozone-based 
chemiluminescence. The median basal [RSNO] in plasma samples (n = 22) was 10 (5–13) nM (interquartile 
range in brackets). In comparison, the median values for basal [RSNO] in the corresponding RBC preparations (n 
= 19) and whole blood samples (n = 19) were higher (p < 0.001) than in plasma, being 40 (30–60) nM and 35 
(25–80) nM, respectively. The median RBC [RSNO] in a separate cohort of healthy subjects (n = 5) was increased 
to 110 (93–125) nM after ingesting BR (12.8 mmol NO3⁻) compared to a corresponding baseline value of 25 
(21–31) nM (Mann-Whitney test, p < 0.01). The median plasma [RSNO] in another cohort of healthy subjects (n 
= 14) was increased almost ten-fold to 104 (58–151) nM after BR supplementation (7 × 6.4 mmol of NO3⁻ over 
two days, p < 0.01) compared to PL. In conclusion, RBC and plasma [RSNO] are increased by BR ingestion. In 
addition to NO2⁻, RSNO may be involved in dietary NO3⁻ metabolism/actions.   
1. Introduction 
Nitric oxide (NO) is a pivotal gaseous molecule that executes mul-
tiple functions in the human body, such as promoting vasodilation and 
lowering blood pressure [1–4], inhibiting platelet aggregation [5] and 
enhancing exercise performance [6–8]. However, abnormalities in the 
bioavailability of NO and/or its reaction products [e.g., nitrate (NO3⁻), 
nitrite (NO2⁻), S-nitrosothiols (RSNO), N-nitrosamines (RNNO) and 
dinitrosyl iron complexes (DNICs)], have been linked to inflammation, 
hypertension, coagulation [9], diabetes mellitus [10] and reduced ex-
ercise tolerance [11]. NO is synthesised in endothelial cells by a reaction 
catalysed by three isozymes of nitric oxide synthase (NOS). These consist 
of neuronal (nNOS), endothelial (eNOS) and inducible (iNOS) isoforms 
of NOS. In the presence of oxygen (O₂) and reduced 
nicotinamide-adenine-dinucleotide phosphate (NADPH), which serve as 
co-substrates, these enzymes catalyse the conversion of L-arginine to 
L-citrulline and NO (the classical NO synthesis pathway) [12,13]. 
However, recent studies have demonstrated that, in humans, dietary 
NO3⁻ may also be converted to NO. This involves the entero-salivary 
circulation of NO3⁻, whereby NO3⁻ is absorbed in the stomach and 
small intestine, enters the blood circulation, and is then concentrated in 
saliva due to active uptake by the salivary glands. Secreted salivary NO3⁻ 
is converted to NO2⁻ in a reaction catalysed by bacterial NO3⁻ reductase 
(see below) in the oral cavity [14–16]. Swallowed NO2⁻ is then chemi-
cally reduced to NO under the acidic conditions of the stomach [17], as 
well as NO2⁻ being absorbed in the gastrointestinal tract and entering the 
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bloodstream. When NO synthesis, catalysed by NOS, is impaired in 
human tissues, NO2⁻ is reduced to NO through several enzymatic and 
non-enzymatic pathways, particularly under hypoxic and acidic condi-
tions, including biochemical reduction catalysed by deoxyhaemoglobin 
[18], deoxymyoglobin (which reduces NO2⁻ to NO at a rate 32 times 
faster than deoxyhaemoglobin) [19] and xanthine oxidase [20,21]. 
S-nitrosothiols (RSNO), also called thionitrites, include both low 
molecular weight RSNO, such as cysteine and glutathione, and high 
molecular weight RSNO such as S-nitrosoalbumin and S-nitro-
sohaemoglobin (SNO-Hb). RSNO are generated in tissues by the reaction 
of reactive nitrogen species (RNS) with thiol (RSH) groups. RSNO play 
an important role in vasodilation [22], inhibition of platelet aggregation 
[23,24], smooth muscle relaxation [25,26], and anti-inflammatory ef-
fects by protecting against ischemia/reperfusion injury [27]. RSNO are 
more stable than NO and are thought to act as NO donor molecules in the 
circulation. It has also been suggested that RSNO may be considered as a 
storage form for intravascular NO, which serves to regulate blood flow 
and oxygen delivery [28]. It is possible that RSNO enter the bloodstream 
after ingestion of green leafy vegetables and beetroot [29], which are 
rich sources of NO3⁻ [30]. In the NO3⁻ - NO2⁻ - NO pathway, NO3⁻ is 
rapidly reduced to NO2⁻ in the mouth by obligate and facultative 
anaerobic bacteria, resulting in a high salivary NO2⁻ concentration. 
Once swallowed, NO2⁻ in the stomach is exposed to a strongly acidic 
milieu (pH is ~1.5–2.0), thereby generating NO, nitrous acid and RNS, 
which promote RSNO formation [31–36]. Gastric and plasma [RSNO] 
are increased after orally administered sodium NO2⁻ and NO3⁻ in hy-
pertensive rats [35], plasma [RSNO] is increased after treatment with 
sodium nitrate (NaNO3) in mice with chronic ischemia [37], and gastric 
[RSNO] is increased after ingestion of inorganic NO3⁻ in humans [36, 
38]. However, it has been reported that plasma [RSNO] is not increased 
after NO3⁻ ingestion in humans [36,39]. 
RSNO, NO3⁻ and NO2⁻ concentrations have rarely been measured 
concurrently after ingestion of NO3⁻, and little is known about how these 
entities distribute themselves amongst the various blood compartments 
in humans. There is a large variation in the reported average baseline 
levels of RSNO in human blood compartments: e.g., the average plasma 
[RSNO] (reported as both mean and median values) varies between 6.3 
nM and 7.19 μM in previous studies [28,39–51], many of which 
included only small sample sizes. In the present study, we hypothesised 
that the ingestion of inorganic NO3⁻ via beetroot juice increases the 
concentrations of RSNO in the red blood cells (RBCs) and plasma of 
healthy volunteers. We measured RSNO concentrations in different 
blood compartments in a relatively large number of human volunteers. 
In addition to measuring RSNO concentrations, we determined the 
concentrations of NO3⁻ and NO2⁻ in plasma, whole blood and RBCs, 
before and after NO3⁻-rich beetroot juice (BR) ingestion. 
2. Materials, human samples and methods 
2.1. Materials 
NaNO3 was obtained from VWR international (Lutterworth, Leices-
tershire, UK). Sodium nitrite (NaNO2), N-ethylmaleimide (NEM), Non-
idet™ P 40 Substitute, mercuric chloride (HgCl2) and 1 M hydrochloric 
acid (HCl) were obtained from Sigma-Aldrich Ltd. (Gillingham, UK). S- 
nitrosoglutathione (GSNO) was obtained from Enzo Life Sciences (Exe-
ter, UK). Sodium iodide (NaI), potassium iodide (KI), iodine (I2), acetic 
acid (99.5%), ethylenediaminetetraacetic acid (EDTA), vanadium (III) 
chloride (VCl3), potassium ferricyanide, sulfanilamide and methanol 
were obtained from Fisher Scientific (Loughborough, Leicestershire, 
UK). Lithium-heparin tubes were obtained from Becton Dickinson UK 
Ltd. (Wokingham, UK). Cannulas were obtained from Becton Dickinson 
Insyte-WTM (Madrid, Spain). NO3⁻-rich beetroot juice (BR; beetroot 
juice containing 6.4 mmol of NO3⁻ per 70 ml; “Beet It Sport”) and NO3⁻- 
depleted beetroot juice (PL; beetroot juice containing 0.04 mmol of NO3⁻ 
per 70 ml) were obtained as gifts from James White Drinks Ltd. (Ipswich, 
UK). The reagents and buffers were made up in ultrapure water (18.2 
MΩ/cm) unless otherwise indicated. 
2.2. Human samples 
The analysed samples were derived from four cohorts of volunteers. 
To measure the basal levels of RSNO in blood compartments, 22 adults 
(mean age ± standard deviation: 24 ± 3 years; 12 males and 10 females) 
were recruited. Seven adults (mean age: 23 ± 5 years; 4 males and 3 
females) were recruited to study the effects of NO3⁻ ingestion on [NO3⁻] 
and [NO2⁻] in blood compartments. The effect of NO3⁻ ingestion on RBC 
[RSNO] in a separate group of 5 adult males (mean age: 26 ± 3 years) 
was investigated. To determine the effects of NO3⁻ ingestion on plasma 
[RSNO], 14 adults (mean age 25 ± 5 years; 10 males and 4 females) were 
recruited. All volunteers gave their written informed consent to partic-
ipate in these studies which were approved by the Institutional Research 
Ethics Committee and conformed to the ethical principles of the 
Declaration of Helsinki. All subjects were healthy, not currently taking 
antibiotics, and none habitually used dietary supplements, mouthwash 
or smoked tobacco. 
2.3. Methods and protocols 
2.3.1. Measurement of basal levels of RSNO in RBCs, whole blood and 
plasma 
The concentrations of RSNO in RBCs, whole blood and plasma were 
determined at baseline (without BR). The healthy subjects (n = 22) 
attended the laboratory on a single occasion, not having consumed a di-
etary NO3⁻ bolus. Blood was collected, using a cannula inserted into the 
subject’s antecubital vein, into two lithium-heparin vacutainers. The first 
collection tube contained final concentrations of ethylenediaminetetra-
acetic acid (EDTA) of 2.5 mM and NEM of 10 mM, respectively, to stabilise 
RSNO and block unreacted thiol groups in plasma samples [40,52,53]. 
The second tube contained EDTA, NEM and ferricyanide at final con-
centrations of 2.5, 10 and 10 mM, respectively. Ferricyanide stabilises 
SNO-Hb in RBC lysate samples by reacting immediately with haemoglo-
bin to form methaemoglobin, hence hindering the auto-capture of NO by 
haem while preserving the SNO bond [48,51,54–57]. A small (1.0 ml) 
whole blood sample was removed from the second tube and added 
immediately to 4.0 ml of hypotonic lysis solution containing EDTA, NEM 
and ferricyanide (at final concentrations of 2.5, 10 and 10 mM, respec-
tively) to lyse the RBCs, before being stored in 1.5 ml Eppendorf tubes at 
− 80 ◦C until analysis. All blood tubes were centrifuged at 3250 g for 10 
min at 4 ◦C. The plasma was then removed from the first tube and stored in 
1.5 ml Eppendorf tubes at − 80 ◦C until analysis. Each RBC sample (1.0 ml) 
from each of the second tubes was immediately mixed with 4.0 ml of 
hypotonic lysis solution, to lyse the RBCs before then being stored in 1.5 
ml Eppendorf tubes at − 80 ◦C until analysis [58]. RSNO measurements 
were performed by treating biological samples (plasma, RBCs and whole 
blood) with 5% acidified sulfanilamide in 1 M HCl to eliminate nitrite 
[42]. Biological samples were also treated with a solution of 0.2% HgCl₂ in 
5% acidified sulfanilamide and 1 M HCl to reduce RSNO to NO2⁻, as well as 
eliminating NO2⁻ [59]. Treatment consisted of mixing the biological 
sample with 5% acidified sulfanilamide with or without 0.2% HgCl₂ to 
give 1/10 dilutions of the reagents. 
The concentrations of RSNO in these plasma, whole blood and RBC 
samples were measured by ozone-based chemiluminescence, a sensitive 
technique for the quantification of RNS. NO is obtained by chemically 
reducing NO3⁻/NO2⁻ or by cleaving NO from its parent compound(s) (e.g., 
RSNO) and that can be achieved by using a specific type of reducing 
solution for each measurement. For the measurement of RSNO, tri-iodide 
(I3⁻) reducing solution was present in the purge vessel at 60 ◦C to convert 
RSNO to NO [60]. I3⁻ solution was prepared by dissolving 2.0 g of potas-
sium iodide (KI) and 1.3 g of I2 in 40 ml of ultrapure water. Then, 140 ml of 
acetic acid was added and mixed thoroughly for 30 min. The chem-
iluminescence reaction was based on the reaction of NO with ozone to 
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produce the excited state of nitrogen dioxide (NO₂*) which returns to a 
ground state by releasing photons of light. The emitted light was detected 
by a photomultiplier tube housed within the NO analyser (Sievers NOA 
280i; Analytix, Durham, UK) to generate an output voltage which was 
proportional to the NO concentration. The electrical signals (mV) were 
sent to a PC (NOAnalysis software v3.21) to facilitate analysis of the re-
sults [61,62]. Because of the low concentrations of total RSNO in human 
blood samples, a large purge vessel (50 ml) was used to ensure sufficient 
signal could be detected. The concentrations of RSNO in the samples were 
determined by using standard curves which were prepared with known 
concentration of S-nitrosoglutathione (GSNO, a low molecular weight 
RSNO) prior to analysis of the samples. A GSNO stock solution was pre-
pared by adding 2.5 mg of GSNO to 1.0 ml of ultrapure water. The final 
concentration of the GSNO stock solution was determined by measuring 
its absorbance at 545 nm by using a Cary 300 UV–vis spectrophotometer. 
The molar extinction coefficient (ε) at 545 nm for GSNO is 17.2 M⁻1cm⁻1 
[63]. Serial dilutions of known concentrations (0–1000 nM) of GSNO 
were used to construct a standard curve by treating the serially diluted 
GSNO solutions with 5% acidified sulfanilamide in 1 M HCl to eliminate 
NO2⁻. The mean correlation coefficient (r2) of GSNO standard curves was 
0.9998. The between–batch coefficient of variation (CV) of the plasma 
RSNO assay was 10.7% (n = 5). To obtain the final chemiluminescence 
signal from RSNO, the signal of each biological sample treated with HgCl₂ 
was subtracted from the signal of the biological sample without HgCl₂. 
2.3.2. Assessment of the effects of BR ingestion on RBC RSNO 
concentrations 
Before we started to measure [RSNO] in RBCs following BR inges-
tion, we wanted to check that when BR (2 × 70 ml; 12.8 mmol NO3⁻) was 
consumed by a second cohort of healthy volunteers (n = 7), there was an 
increase in the [NO3⁻] and [NO2⁻] in plasma (as previously reported; for 
example, see Refs. [64–67]). We also measured [NO3⁻] and [NO2⁻] in 
whole blood and RBCs (Supplementary Figs. 1–2). Once we had 
confirmed that this amount of BR (12.8 mmol NO3⁻) did indeed cause an 
increase in [NO3⁻] and [NO2⁻], we measured [RSNO] in RBCs. NO3⁻-rich 
beetroot juice (2 × 70 ml; 12.8 mmol NO3⁻) was administered orally to a 
third cohort of healthy volunteers (n = 5). The participants were 
instructed to arrive at the laboratory for one visit. In the morning, 
venous blood was collected using a cannula inserted into the subject’s 
antecubital vein, and blood was collected into lithium-heparin vacu-
tainers containing EDTA, NEM and ferricyanide (as described above). 
Blood samples were collected at rest (baseline) and 2 h after consuming 
BR. The whole blood was centrifuged at 3250 g for 10 min at 4 ◦C, to 
separate the plasma and buffy coat from the packed RBCs. A small RBC 
sample (1.0 ml) was removed and added to 4.0 ml of hypotonic lysis 
solution containing EDTA, NEM and ferricyanide (at final concentra-
tions of 2.5, 10 and 10 mM, respectively) to lyse the RBCs, before being 
stored at − 80 ◦C until analysis. 
2.3.3. Determination of the effects of BR ingestion on plasma RSNO 
concentrations 
BR or PL (7 × 70 ml) were administered orally to the fourth cohort of 
healthy volunteers (n = 14) to determine the effect of medium-term 
dietary supplementation with BR on [RSNO] in plasma. This study fol-
lowed a double-blind, placebo controlled, crossover study design. The 
volunteers were instructed to arrive at the laboratory for three separate 
visits in a fully rested and hydrated state, at least 3 h postprandial and 
having avoided strenuous exercise in the 24 h preceding each visit. The 
blood samples were collected during the first visit at baseline (i.e., 
without any NO3⁻ supplementation before taking the samples), but at 
the second and third visits each of the volunteers had consumed 7 × 70 
ml of BR (44.8 mmol NO3⁻) or PL over 48 h before collecting the blood 
samples. The protocol of this experiment was previously described in 
detail (see Ref. [68]). It involved the ingestion of a higher dose of NO3⁻ 
than in previous short-term BR supplementation experiments, resulting 
in plasma NO2⁻ rising by ~800% in the BR group from pre-to 
post-donation [68]. In the previous published study [68], from which 
the presently analysed samples were derived, no adverse events were 
noted. The [RSNO] in the plasma samples was measured by ozone-based 
chemiluminescence as described above [62]. 
2.3.4. Statistical analyses 
All calculations were performed using Graph-Pad Prism software 
(Graph-Pad Software version 5.04). The data are presented as the me-
dian with interquartile ranges [IQR, 25% (lower; LQ) and 75% (upper; 
UQ)]. The Mann-Whitney U test was used to determine the statistical 
significance of differences between group median values. In all cases, p 
≤ 0.05 was considered statistically significant and “n.s.” denotes “not 
statistically significant”. Spearman’s correlation coefficient (rs) was 
used to explore significant relationships between the levels of [NO3⁻], 
[NO2⁻] and [RSNO] across the blood compartments and changes in the 
levels of [NO3⁻], [NO2⁻] and [RSNO] before and after ingesting BR. A 
Bonferroni correction was applied to adjust for the multiple tests against 
the same data set. 
3. Results 
3.1. Confirmation that BR ingestion resulted in a significant increase in 
plasma [NO3⁻] and [NO2⁻] 
Typical examples of chemiluminescence time-traces when detecting 
NO3⁻ and NO2⁻, together with representative standard curves, are shown 
in Supplementary Fig. 1. As expected, the ingestion of BR containing 
12.8 mmol of NO3⁻ resulted in statistically significant increases in the 
median plasma concentrations of both NO3⁻ and NO2⁻ compared with 
baseline and PL consumption (Supplementary Fig. 2). 
3.2. Measurement of basal levels of RSNO in RBCs, whole blood and 
plasma 
We were able to confirm the expected effects of the reagents (5% 
sulfanilamide and 0.2% HgCl₂) on the observed chemiluminescence 
signals from the reagent-treated samples comprising the GSNO standard 
curve (Supplementary Fig. 3). A representative RSNO signal time-trace 
and standard curve is shown in Fig. 1. The median concentrations 
(with interquartile range in brackets) of total RSNO in healthy human 
volunteers at baseline (i.e., prior to any NO3⁻ supplementation) were 40 
(30-60) nM, 35 (25-80) nM and 10 (5-13) nM in RBCs (n = 19), whole 
blood (n = 19) and plasma (n = 22), respectively (Fig. 2). The chem-
iluminescence assay of the total [RSNO] in these biological samples 
indicated that levels of total RSNO were significantly higher in RBCs and 
whole blood (p < 0.05) compared to matched plasma from the same 
individuals. Plasma [RSNO] at baseline exhibited a significant inverse 
correlation with whole blood [RSNO] (rs = − 0.53, p < 0.05) from the 
same subjects (Fig. 3a). There was a trend towards a negative correlation 
between the baseline [RSNO] in plasma versus RBCs (Fig. 3b) (rs = −
0.44, p = 0.07). In contrast, there was no correlation (rs = 0.001) be-
tween [RSNO] in whole blood versus RBCs (Fig. 3c). 
3.3. Assessment of the effects of BR ingestion on RBC RSNO 
concentrations 
We determined the effects of ingestion of 2 × 70 ml shots of 
concentrated BR on [NO3⁻] and [NO2⁻] in RBCs, whole blood and 
plasma. As expected from earlier studies (for example, Refs. [64–67]), 
we found that the median RBC, whole blood and plasma [NO3⁻] and 
[NO2⁻] were significantly increased after ingesting BR (p < 0.05), 
compared to both baseline and PL consumption (Supplementary Fig. 2). 
In a separate group of healthy volunteers (n = 5), the median RBC 
[RSNO] was 25 (21-31) nM before ingesting BR and this was signifi-
cantly increased to 110 (93–125) nM after ingesting BR (p < 0.01) 
(Fig. 4). 
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3.4. Determination of the effects of BR ingestion on plasma RSNO 
concentrations 
Total [RSNO] measurements were performed in 14 healthy volun-
teers before and after medium-term (48 h), repeated (7 × 70 ml), PL and 
BR supplementation. The median plasma [RSNO] of healthy volunteers 
at baseline and after ingesting PL and BR was 12 (11-13) nM, 11 (7-14) 
nM and 104 (58–151) nM, respectively (Fig. 5). The results indicated 
that the median total [RSNO] was significantly increased after ingesting 
BR (p < 0.05) compared to baseline and PL consumption. There was no 
statistically significant difference between median total [RSNO] in the 
BL group compared with the PL group. The values for [NO3⁻] and [NO2⁻] 
in this study of 14 healthy volunteers were previously reported [68]. 
There were no statistically significant correlations between the presently 
reported plasma [RSNO] and either [NO3⁻] or [NO2⁻]. 
4. Discussion 
The main original findings of this study, which are consistent with 
our hypothesis, are that the RBC and plasma [RSNO] were increased 
after ingestion of BR, compared to baseline and PL in healthy volunteers. 
Plasma [NO3⁻] and [NO2⁻], and whole blood and RBC [NO3⁻] and 
[NO2⁻], were also increased after BR ingestion. It is possible that the 
increases in RBC and plasma [RSNO] and RBC [NO2⁻] may be involved 
in many of the diverse physiological effects reported following the 
ingestion of NO3⁻ because we have shown here that it is not solely 
plasma [NO2⁻] that is elevated following dietary NO3⁻ ingestion. 
Fig. 1. Typical GSNO standard curve obtained from the depicted ozone-based chemiluminescence traces. Panel (a): serial dilutions of a GSNO solution treated 
with a solution of 5% acidified sulfanilamide, were injected in duplicate into tri-iodide solution to obtain the chemiluminescence signal peaks which were quantified 
by calculating the area under the curve. The inset panel shows the traces from the lowest GSNO concentration, on an expanded y-axis scale for clarity. ↓ indicates the 
time-point at which the analysed sample (500 μl) was injected. Panel (b): an example of the resulting standard curve. The results shown are typical of those obtained 
in >20 experiments. 
Fig. 2. Scatter plot showing the concentrations of total RSNO in plasma, 
RBCs and whole blood in healthy volunteers at baseline. The graph shows 
that the median levels of total RSNO in healthy volunteers were higher (***p <
0.001) in RBCs and whole blood compared to plasma. The long horizontal bar 
represents the median value in each group, whilst the short horizontal bars 
represent the interquartile range. 
Fig. 3. Scatter plots showing the correlations of baseline total [RSNO] between blood compartments (plasma, whole blood and RBCs). Panel (a) shows that 
the baseline [RSNO] in plasma was inversely correlated (rs = − 0.53, p = 0.029) with whole blood [RSNO] from the same subjects. Panel (b) shows the observed 
trend towards a negative correlation between the baseline [RSNO] in plasma and in RBCs, but this was not statistically significant (rs = − 0.44, p = 0.07). Panel (c) 
shows that the baseline [RSNO] in whole blood was not correlated (rs = 0.001, p = 0.99) with RBC [RSNO]. The solid line indicates the estimated regression line. 
Spearman’s rank correlation coefficient (rs) was calculated from n = 17 subjects. 
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4.1. RBC, whole blood and plasma [RSNO] at baseline 
Total RSNO in baseline human blood samples are present at low 
concentrations. In previous studies [28,39,44–47,69], the reported 
levels of total RSNO, in plasma of healthy individuals, have varied 
widely (between 6.3 and 7190 nM), possibly due to the use of different 
analytical methodologies. Early plasma RSNO measurements seemed to 
give relatively high concentrations, in the micromolar range. But, more 
recently, the reported values have become more consistent, at around 
10 nM. In the present study, we used a large purge vessel (50 ml) to 
allow the injection of a larger volume of sample, to reduce foaming and 
obtain sufficient signal peak-to-noise ratios from the chemiluminescence 
Fig. 4. Representative chemiluminescence time- 
traces for RBC RSNO detection, and a scatterplot 
showing the calculated concentrations of the 
total RSNO in RBCs of healthy volunteers. Panels 
(a) and (b) show examples of chemiluminescence 
signal peaks from the ozone-based chem-
iluminescence during the measurement of RSNO in 
RBC samples from healthy volunteers, following 
sample injections (one with 5% sulfanilamide in 1 
M HCl only (“Acid Sulf ") and another one with 
“Acid Sulf " and 0.2% HgCl₂) after individuals had 
ingested beetroot juice (BR) or at baseline (BL). ↓ 
indicates the time-point at which the analysed 
sample (500 μl) was injected. The final RSNO levels 
were obtained by subtracting the values of samples 
treated with HgCl₂ from those without HgCl₂. Panel 
(c) shows that the median concentration of RSNO in 
RBCs of healthy subjects was significantly higher 
(**, p < 0.01) after ingesting BR juice compared to 
the median baseline RSNO concentration without 
supplementation (n = 5).   
Fig. 5. Representative chemiluminescence signal traces for plasma RSNO detection, and a scatterplot showing the calculated concentrations of the total 
RSNO in the plasma of healthy volunteers at baseline, after ingesting the placebo juice, or after ingesting NO3⁻-rich beetroot juice. The figure shows (in 
panels a and b) examples of the time courses of the chemiluminescence signal peaks when measuring the NO release from plasma RSNO in volunteers who had 
received NO3⁻-rich beetroot juice. Panel (a) shows typical results from injecting samples treated with 5% acidified sulfanilamide in 1 M HCl only (“Acid Sulf"), and 
panel (b) shows the signal traces for the same injected samples treated with 5% acidified sulfanilamide and 0.2% HgCl₂ in 1 M HCl (“Acid Sulf HgCl2′′). The acid 
sulfanilamide and sulfanilamide/HgCl₂ solutions were diluted 1/10 when added to biological samples. In panels (a) and (b), ↓ indicates the time-point at which the 
analysed sample (500 μl) was injected. The final RSNO concentrations were calculated by subtracting the concentrations of the samples treated with HgCl₂ from the 
concentrations of the samples without HgCl₂. Panel (c) shows: the baseline levels of RSNO for a group of individuals (n=7) before administration of placebo (NO3⁻- 
depleted) beetroot juice (BL-PL), the levels of RSNO for the same group after ingesting placebo beetroot juice (PL), the baseline levels of RSNO for another group of 
individuals (n=7) before administration of NO3⁻-rich beetroot juice (BL-BR), and the levels of RSNO for the group after ingesting NO3⁻-rich beetroot juice (BR). Panel 
(c) shows that the median level of total RSNO in the plasma of healthy volunteers was significantly higher (**, p<0.01) after ingesting BR, compared to both the BL- 
BR and PL groups. However, there were no statistically significant differences between BL-PL, PL and BL-BR in relation to the median levels of total RSNO. 
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traces. In earlier studies [45,48,50], only one type of RSNO species was 
measured in whole blood and RBC pellets, namely S-nitro-
sohaemoglobin (SNO-Hb). In these studies, RBC lysates from whole 
blood and RBC pellets were passed through Sephadex G25 size exclusion 
columns [45,48,50], to remove the small thiols and separate SNO-Hb, 
which has a relatively high molecular weight, in RBC lysates. Howev-
er, in the present study all RSNO species in RBCs and whole blood were 
measured. Also, the levels of total RSNO in blood compartments were 
observed in a larger number of subjects (RBCs and whole blood, n = 19; 
plasma, n = 22), compared with earlier studies which mostly included a 
smaller number of subjects (between 3 and 10) [28,39,42–48]. 
In the present study, the basal [RSNO] was similar in RBCs (40 (30- 
60) nM) and whole blood (35 (25-80) nM); but these values were 
significantly higher than in matched plasma (10 (5-13) nM). The hae-
matocrit is typically about 45% for human blood, which is consistent 
with our observation that the median concentration of RSNO in whole 
blood had a value which was intermediate between the median con-
centrations of RSNO in plasma and RBCs. Interestingly, there was a 
significant inverse correlation (rs = − 0.53, p < 0.05) between [RSNO] 
in whole blood and [RSNO] in plasma (Fig. 3a). It seems possible that 
this inverse correlation might be explained, at least in part, by an inverse 
association between RBC [RSNO] and plasma [RSNO] (Fig. 3b), 
although this trend was not statistically significant. Whole blood 
[RSNO] showed no correlation with RBC [RSNO] (Fig. 3c). These re-
lationships between [RSNO] in different blood compartments might 
suggest there is a ’’fixed pool’’ of RSNO in whole blood which can be 
distributed in different proportions between the RBC and plasma com-
partments. It has been reported that protein disulfide isomerase (PDI) 
can be S-nitrosated, such that PDI-SNO may be involved in the transport 
of intracellular NO to the cell surface and thence to the plasma [70]. 
Therefore, when the RBC [RSNO] is increased, the RBC PDI may be 
predicted to become S-nitrosated which could be involved in the 
transport of RSNO to the cell surface and then to the plasma. This 
mechanism might explain why a low [RSNO] in RBCs is associated with 
high [RSNO] in plasma and vice versa. 
4.2. RSNO concentrations in RBCs and plasma following nitrate 
supplementation 
We observed an increase in the levels of total RSNO in RBCs of 
healthy volunteers after ingesting BR, compared to baseline values. To 
our knowledge, this is the first study to report the concentrations of 
RSNO in RBCs from healthy humans after ingesting nitrate. One possible 
reason why earlier investigators did not observe an increase in blood 
RSNO after NO3⁻ ingestion might be because they did not analyse RBCs 
[36,39]. Our results also showed an increase in the levels of total RSNO 
in plasma of healthy volunteers after ingesting BR, which is in contrast 
to two previous studies [36,39]. This may be because a nitrate salt was 
used (pure potassium nitrate [36] or sodium nitrate [39]), whereas we 
used BR which may contain other components influencing the uptake 
and/or metabolism of nitrate [71,72]. For example, quercetin (a poly-
phenol) is one of the phytochemicals in BR [73,74]. Polyphenols may 
inhibit the formation of RSNO [75–77]. On the other hand, the ingestion 
of pure quercetin resulted in a significant increase in plasma RSNO in 
both normotensive volunteers [78] and 2K1C rats [79], potentially 
explaining why BR administration increases plasma RSNO, whilst pure 
sodium nitrate does not. Also, the placebo juice had no effect on RSNO 
levels in the present study, consistent with the effect of polyphenols in 
BR being synergistic with nitrate but absent when nitrate is removed 
from the juice. 
In the Lundberg and Govoni study [39], another potential reason 
why an increase in [RSNO] in human plasma was not shown, after 
ingested nitrate, is that plasma [RSNO] was only monitored for 1.5 h 
after ingestion of sodium nitrate (10 mg/kg), whereas we monitored 
plasma [RSNO] for 2 h in the present study. In the Richardson et al. 
study [36] the amount of ingested NO3⁻ (2 mmol) was much smaller 
compared to our study (6.4 mmol) and may not have been physiologi-
cally meaningful. It has been shown that 3.5 mmol of dietary NO3⁻ (as 
beetroot juice), does not result in a blood pressure-lowering effect in 
healthy human volunteers with normal blood pressure [80,81]. 
The increased RBC and plasma RSNO concentrations observed in the 
present study could be due, at least in part, to the formation in the 
stomach of RSNO which are then absorbed. It has previously been re-
ported that RSNO are formed in the human stomach after inorganic 
nitrate ingestion [36,38]. In peripheral blood, RSNO could be formed by 
the reaction of NO with thiyl radicals (RS⋅) or by a nitrosating species 
such as dinitrogen trioxide (N2O3) in the presence of RSH groups [52, 
82]. Other studies have also shown that the plasma concentration of 
total nitroso species (RXNO), which includes RSNO and N-nitrosamines 
(RNNO), was increased after ingestion of BR [83,84]. However, these 
two earlier studies did not distinguish RSNO from N-nitrosamines by 
using HgCl₂ to remove RSNO; these studies only used sulfanilamide to 
eliminate nitrite. Thus, the effects of BR ingestion on RXNO and RSNO 
should not be considered directly comparable. In the present study, the 
mercury-stable peaks in Fig. 4a, b and 5b could be nitroso compound(s) 
that remained after incubation with HgCl2, such as N-nitrosamines, as 
suggested by previous studies [40,85]. Finally, dinitrosyl iron complexes 
(DNICs) cannot be excluded as contributors to the mercury-sensitive 
peaks in the same figures, as HgCl2 has been shown to accelerate the 
degradation of DNICs [86]. The future application to human blood 
samples of new ozone-based chemiluminescence methods for detecting 
DNICs may help to resolve this issue [87]. 
The levels of plasma NO2⁻ were increased following dietary NO3⁻ [5, 
18,88–90], and the in vivo conversion of NO3⁻ to NO2⁻ appears to be 
involved in many diverse physiological effects of dietary NO3⁻ such as 
vasodilation, lowering blood pressure and inhibition of platelet aggre-
gation. The possibility remains, that after dietary NO3⁻ ingestion, these 
various physiological effects might also be mediated by the increased 
RBC and plasma [RSNO]. In previous studies, it has been shown that 
RSNO play a significant role in many positive physiological effects such 
as vasorelaxation and platelet inhibition [22–26,41]. 
4.3. Conclusion 
The median RSNO concentrations in plasma and RBCs from healthy 
volunteers were significantly higher after ingesting BR compared with 
PL and/or baseline concentrations. These results contrast with previous 
studies that have not shown increases in plasma [RSNO] and this may be 
because these studies used pure inorganic NO3⁻ and/or smaller doses of 
NO3⁻; the present study used BR, which may contain other components 
influencing the uptake/metabolism of NO3⁻. The observed inverse cor-
relation between [RSNO] in whole blood versus [RSNO] in plasma at 
baseline, and a trend towards an inverse correlation between RBC 
[RSNO] and plasma [RSNO], suggests that the generated RSNO may be 
distributed in different proportions between the plasma and RBC com-
partments. These findings shed light on the distribution of different RNS 
between the various blood compartments and may help to improve the 
potential therapeutic strategies for use of NO3⁻ supplementation. 
Finally, measuring only plasma NO3⁻ and NO2⁻ may be insufficient to 
gain an understanding of the various physiological effects of dietary 
nitrate, which might be mediated – at least in part – by the increased 
RSNO in blood compartments. 
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